Adalimumab (Humira) TNF inhibirajući antiinflamatorni je lek. Adalimumab je ljudsko monoklonalno antitelo protiv TNF-alfa. On se proizvodi primenom rekombinantne DNK tehnologije koristeći sisarski ekspresioni sistem. Adalimumab se sastoji od 1330 [aminokiselina].[2][3][4][5]

Adalimumab
Klinički podaci
Robne marke Humira, Humira (Abbott Laboratories), Humira Pen
AHFS/Drugs.com Monografija
Identifikatori
CAS broj 331731-18-1
ATC kod L04AB04
DrugBank DB00051
ChEMBL[1] CHEMBL1201580 DaY
Hemijski podaci
Formula C6428H9912N1694O1987S46 
Mol. masa 144190.3
Farmakokinetički podaci
Poluvreme eliminacije 10-20 dana
Farmakoinformacioni podaci
Trudnoća ?
Pravni status
Način primene Subkutano

Reference uredi

  1. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.  edit
  2. PDB sequence Link:http://www.rcsb.org/pdb/download/downloadFile.do?fileFormat=FASTA&compression=NO&structureId=1IGT[mrtav link]
  3. Patent Information Link:http://www.freepatentsonline.com/6090382.html
  4. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. DOI:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682. 
  5. David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. DOI:10.1093/nar/gkm958. PMC 2238889. PMID 18048412. 

Literatura uredi

Spoljašnje veze uredi